Conventional external beam radiation has proved its profit in pediatric tumors; but its complications have limited it in therapeutical approach. Intraoperative radiotherapy delivers a high single dose in residual tumor or high risk areas during surgery. In our center, during last two years, 7 patients have been candidates to surgery with intraoperative radiotherapy (the age range was between 5 months-17 years; mean 8.5 years). Two patients were excluded of our protocol because of their intraoperative stage. Patients tumors types were: neuroblastoma (n = 3; stage III and IV), soft tissue sarcomas (n = 1) and Ewing's sarcoma (n = 1). The radiation doses ranged from 500 cGyto-1200 cGy. Local control tumor was achieved in 4 patients and no-complications were present secondary to surgery or intraoperative radiotherapy. Intraoperative radiotherapy seems to be a feasible treatment which might promote local control in pediatric tumors with protection of normal tissues and could be an excellent complement in special cases.
Download full-text PDF |
Source |
---|
Cancers (Basel)
January 2025
Department of Ophthalmology, University of Lübeck, University Medical Center Schleswig-Holstein, Campus Lübeck, 23562 Lübeck, Germany.
: Accurate target definition, treatment planning and delivery increases local tumor control for radiotherapy by minimizing collateral damage. To achieve this goal for uveal melanoma (UM), tantalum fiducial markers (TFMs) were previously introduced in proton and photon beam radiotherapy. However, TFMs cause pronounced scattering effects in imaging that make the delineation of small tumors difficult.
View Article and Find Full Text PDFBrain Sci
December 2024
Department of Medical and Surgical Sciences and Advanced Technologies "G.F. Ingrassia", Neurological Surgery, Policlinico "G. Rodolico-San Marco" University Hospital, University of Catania, 95124 Catania, Italy.
: Elastic image fusion (EIF) using an intraoperative CT (iCT) scan may enhance neuronavigation accuracy and compensate for brain shift. : To evaluate the safety and reliability of the EIF algorithm (Virtual iMRI Cranial 4.5, Brainlab AG, Munich Germany, for the identification of residual tumour in glioblastoma surgery.
View Article and Find Full Text PDFStrahlenther Onkol
January 2025
Department of Radiation Oncology, University Hospital Zurich, University of Zurich, Rämistrasse 100, 8091, Zurich, Switzerland.
The integration of artificial intelligence (AI) into radiotherapy has advanced significantly during the past 5 years, especially in terms of automating key processes like organ at risk delineation and treatment planning. These innovations have enhanced consistency, accuracy, and efficiency in clinical practice. Magnetic resonance (MR)-guided linear accelerators (MR-linacs) have greatly improved treatment accuracy and real-time plan adaptation, particularly for tumors near radiosensitive organs.
View Article and Find Full Text PDFAnal Chem
January 2025
State Key Laboratory of Supramolecular Structure and Materials, College of Chemistry, Jilin University, Changchun 130012, China.
As the most common and lethal cancer of the female gonads, ovarian cancer (OC) has a grave impact on people's health. OC is asymptomatic, insidious in onset, difficult to diagnose and treat, fast-growing, and easy to metastasize and has poor prognosis and high mortality. How to detect OC as early as possible and treat it without side effects has become a challenging medical problem.
View Article and Find Full Text PDFWorld J Urol
January 2025
Department of Urology, Hospital of Vall Hebron, Autonomous University of Barcelona, Barcelona, Spain.
Introduction: Open ureteroenteric reimplantation (OUER) of ureteroenteric strictures (UESs) is related to important morbidity. Robot-assisted ureteroenteric reimplantation (RUER) has been proposed to provide similar outcomes with lower morbidity. We aimed to compare perioperative and functional outcomes between RUER and OUER.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!